経口避妊薬の使用と,モヤモヤ病の患者における急性性血栓性脳卒中リスク
Shoko Hara1, Shota Takahashi1, Ayako Fudono2
1Department of Neurosurgery, Institute of Science Tokyo, Tokyo, Japan.
NMC case report journal
|February 17, 2026
まとめ
口服避妊薬は,血栓栓塞栓性イベントを通じて,モヤモヤ病の患者における急性性不全性脳卒中のリスクを高めることがあります. しかし,このリスクは,患者の教育と婦人科医のコミュニケーションを強調して,再血管化半球では管理可能なように見える.
科学分野:
- 神経学 神経学とは
- 血管神経学 血管神経学
- 神経科学は神経科学である.
背景:
- モヤモヤ病は,頭蓋内動脈の漸進的な狭窄によって特徴づけられる珍しい脳血管疾患です.
- モヤモヤ病の患者における経口避妊薬の使用と,不全性脳卒中リスクに対するそれらの潜在的な影響は,まだ完全に理解されていません.
研究 の 目的:
- モヤモヤ病と診断された女性患者における経口避妊薬の使用と急性不全性脳卒中の発生率の関連性を調査する.
- この患者集団における脳卒中発生の潜在的メカニズムを探求する.
主な方法:
- モヤモヤ病の女性患者589人 (12歳~49歳) を2012~2023年に遡って調査した.
- 口服避妊薬の使用歴,脳卒中発生のタイミング,放射線画像パターンの評価.
- 脳卒中のメカニズムの評価は,血栓塞栓性イベントと,以前の再血管化の役割に焦点を当てて行われます.
主要な成果:
- 12人の患者が経口避妊薬を使用し,5人は使用中に脳卒中後のモヤモヤ病と診断されました.
- フォローアップ期間中に経口避妊薬を服用した7人の患者のうち2人が数ヶ月後に脳卒中を発症した.
- 前回の再血管化を受けた半球では脳卒中は発生しなかったが,画像検査では,血栓塞栓的メカニズムが示唆された.
結論:
- 経口避妊薬は,血栓栓塞栓経路経由で,モヤモヤ病の患者において,不全性脳卒中のリスクを増加させる可能性があります.
- リスクは,疾患が安定している再血管化半球において低いようです.
- 患者教育と婦人科医の協力は,避妊と月経障害の管理に不可欠です.
関連する概念動画
Ischemic Heart Disease: Overview
3.5K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.5K
Acute Coronary Syndrome I: Introduction
1.1K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.1K
Coronary Artery Disease IV: Preventive Measures
738
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
738
Acute Coronary Syndrome III: Diagnostic Studies
298
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
298
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
468
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
468
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K


